Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM39C47)

Drug Name

N-Octyl-beta-valienamine Drug Info

Synonyms

(1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922580; N-Octylvalienamine; CHEMBL1234952; SCHEMBL21067585; BDBM50358322; DB08321; Q27097540; OEV

Indication

Disease Entry	ICD 11	Status	REF
Gaucher disease	5C56.0Y	Preclinical	[1]

Cross-matching ID

PubChem CID: 9817381
TTD Drug ID: DM39C47

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucosylceramidase (GBA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Velaglucerase alfa	DM4BOAS	Gaucher disease type I		Approved	[3]
Taliglucerase alfa	DM3PZXN	Metabolic disorder	5C50-5D2Z	Approved	[4]
Isofagomine tartrate	DM2RS0V	Metabolic disorder	5C50-5D2Z	Phase 2	[5]
Afegostat	DMRWSKX	Gaucher disease	5C56.0Y	Discontinued in Phase 2	[1]
NCGC607	DMXG0O1	Gaucher disease	5C56.0Y	Preclinical	[6]
2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	DMOUG6Y	Discovery agent	N.A.	Investigative	[7]
L-Isofagomine	DM6RKOC	Discovery agent	N.A.	Investigative	[8]
(2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol	DM7GI94	Discovery agent	N.A.	Investigative	[9]
N-(Propylamide-acetophenone)-1-deoxynojirimycin	DMXI4V8	Discovery agent	N.A.	Investigative	[10]
(2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol	DMIQNX9	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucosylceramidase (GBA)	TT1B5PU	GLCM_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
2	Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72.
3	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5	Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008 Nov 3;9(16):2650-62.
6	A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci. 2016 Jul 13;36(28):7441-52.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
9	Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50.
10	Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. Bioorg Med Chem. 2010 Jan 1;18(1):267-73.